Triumvira Immunologics, a clinical-stage company developing groundbreaking T cell therapies to fight solid tumors, today announced a clinical trial collaboration and supply agreement with Merck. The upcoming TACTIC-2 trial will evaluate the use of Triumvira’s novel autologous cell therapy TAC01-HER2, both as a standalone treatment and in combination with Merck’s anti-PD-1 therapy KEYTRUDA®, to treat HER2-positive solid tumors. This groundbreaking initiative is a promising step forward in the fight against cancer.
At Triumvira, we are thrilled to join forces with Merck to explore the potential of adding an immune checkpoint inhibitor like KEYTRUDA to our TAC01-HER2 treatment for relapsed or refractory solid tumors. We believe that releasing inhibitory PD-L1/PD1 signaling in T cells with this approach could unlock improved and durable therapeutic responses and bring much-needed new drug therapies to those who don’t respond to existing treatments. Paul Lammers, M.D., M.Sc., Chief Executive Officer of Triumvira, said, “We are pleased to be able to bring this hope to patients.”
At the 2022 European Society for Medical Oncology Congress, Triumvira unveiled exciting data from the TACTIC-2 Phase 1/2 trial that showcased the safety and potential efficacy of TAC01-HER2 in patients with HER2-positive solid tumors. Currently, the trial is enrolling participants at five clinical trial sites across the U.S. and Canada, with the expansion phase expected to launch in 2023. The trial will evaluate TAC01-HER2 as a monotherapy, as well as in combination with KEYTRUDA in patients with HER2-positive solid tumors. This breakthrough trial offers a promising outlook for those affected by HER2-positive cancers.
We are thrilled by the promising safety and efficacy data that we have observed in our TACTIC-2 trial. This has the potential to revolutionize the treatment of HER2-expressing solid tumors. We are further excited to collaborate with Merck to evaluate the efficacy of TAC01-HER2 in combination with KEYTRUDA. This could be a major leap forward in cancer therapy.
Merck and Triumvira have come together to launch a Phase 1/2 clinical trial, TACTIC-2, to assess the safety and efficacy of Merck’s KEYTRUDA. The two companies have formed a Joint Development Committee to review the trial results, and further information can be found at ClinicalTrials.gov using ClinicalTrials.gov Identifier NCT04727151. It’s an exciting collaboration that promises to bring much-needed breakthroughs to the healthcare field.
KEYTRUDA® is a revolutionary treatment that has been developed by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, N.J., USA. This powerful immunotherapy drug is transforming the way we approach cancer, offering a new level of hope and optimism to those who are facing a difficult diagnosis. With KEYTRUDA®, these individuals can now look to the future with a newfound belief that they can overcome their cancer and reclaim control of their lives.
About Triumvira Immunologics
Triumvira Immunologics, Inc. is revolutionizing cancer treatments with their pioneering T cell therapeutics. Their proprietary T cell Antigen Coupler (TAC) technology activates natural T cell functions to target solid tumors in a way that is distinct from traditional CAR-T and engineered T cell receptor (TCR) therapies. Based in Austin, Texas, with research facilities in Hamilton, Ontario, and South San Francisco, California, Triumvira is leading the way in bringing hope to those suffering from the devastating effects of cancer.